Montenegro Marcelo F, Sundqvist Michaela L, Larsen Filip J, Zhuge Zhengbing, Carlström Mattias, Weitzberg Eddie, Lundberg Jon O
From the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (M.F.M., M.S., Z.Z., M.C., E.W., J.O.L.); and Åstrand Laboratory, The Swedish School of Sport and Health Sciences, Stockholm, Sweden (F.J.L.).
Hypertension. 2017 Jan;69(1):23-31. doi: 10.1161/HYPERTENSIONAHA.116.08081. Epub 2016 Oct 31.
Inorganic nitrate and nitrite from dietary and endogenous sources are metabolized to NO and other bioactive nitrogen oxides that affect blood pressure. The mechanisms for nitrite bioactivation are unclear, but recent studies in rodents suggest that gastric acidity may influence the systemic effects of this anion. In a randomized, double-blind, placebo-controlled crossover study, we tested the effects of a proton pump inhibitor on the acute cardiovascular effects of nitrite. Fifteen healthy nonsmoking, normotensive subjects, aged 19 to 39 years, were pretreated with placebo or esomeprazole (3×40 mg) before ingesting sodium nitrite (0.3 mg kg), followed by blood pressure monitoring. Nitrite reduced systolic blood pressure by a maximum of 6±1.3 mm Hg when taken after placebo, whereas pretreatment with esomeprazole blunted this effect. Peak plasma nitrite, nitrate, and nitroso species levels after nitrite ingestion were similar in both interventions. In 8 healthy volunteers, we then infused increasing doses of sodium nitrite (1, 10, and 30 nmol kg min) intravenously. Interestingly, although plasma nitrite peaked at similar levels as with orally ingested nitrite (≈1.8 µmol/L), no changes in blood pressure were observed. In rodents, esomeprazole did not affect the blood pressure response to the NO donor, DEA NONOate, or vascular relaxation to nitroprusside and acetylcholine, demonstrating an intact downstream NO-signaling pathway. We conclude that the acute blood pressure-lowering effect of nitrite requires an acidic gastric environment. Future studies will reveal if the cardiovascular complications associated with the use of proton pump inhibitors are linked to interference with the nitrate-nitrite-NO pathway.
来自饮食和内源性来源的无机硝酸盐和亚硝酸盐会代谢为一氧化氮(NO)和其他影响血压的生物活性氮氧化物。亚硝酸盐生物活化的机制尚不清楚,但最近在啮齿动物中的研究表明,胃酸可能会影响这种阴离子的全身效应。在一项随机、双盲、安慰剂对照的交叉研究中,我们测试了质子泵抑制剂对亚硝酸盐急性心血管效应的影响。15名年龄在19至39岁之间的健康非吸烟、血压正常的受试者,在摄入亚硝酸钠(0.3 mg/kg)之前,先接受安慰剂或埃索美拉唑(3×40 mg)预处理,随后进行血压监测。服用安慰剂后再摄入亚硝酸盐时,收缩压最多降低6±1.3 mmHg,而埃索美拉唑预处理则减弱了这种效应。两种干预措施中亚硝酸盐摄入后血浆亚硝酸盐、硝酸盐和亚硝基物质的峰值水平相似。然后,我们对8名健康志愿者静脉输注递增剂量的亚硝酸钠(1、10和30 nmol/kg/min)。有趣的是,尽管血浆亚硝酸盐峰值水平与口服亚硝酸盐时相似(约1.8 μmol/L),但未观察到血压变化。在啮齿动物中,埃索美拉唑不影响对NO供体DEA NONOate的血压反应,也不影响对硝普钠和乙酰胆碱的血管舒张反应,表明下游NO信号通路完整。我们得出结论,亚硝酸盐的急性降压作用需要酸性胃环境。未来的研究将揭示与使用质子泵抑制剂相关的心血管并发症是否与干扰硝酸盐-亚硝酸盐-NO途径有关。